Background: Trans-arterial chemoembolization (TACE) and radiofrequency ablation (RFA) are widely used interventional procedures in treatment of HCCs. ADC value can be used in evaluating their efficacy in order to rule out or in residual tumor tissue. Aim: To assess the role of DWI and ADC value in evaluating HCCs post TACE and REA. Patients and methods: 36 patients with 40 HCCs were included, and 28 lesions were treated with TACE and 12 with RFA. All lesions were evaluated by DWI and ADC value measurement before and after interventional management. Results: 32/40 lesions responded to treatment and 8 lesions had not. ADC values were significantly higher in lesions that responded to TACE or RFA than in non-responding lesions. The mean ADC of the lesions before treatment was 1.27 ± 0.25 Â 10 À3 mm 2 /s, and increased after treatment in responding lesions to reach 1.57 ± 0.22 Â 10 À3 mm 2 /s with a statistically significant difference (P = 0.002). Responding lesions showed significantly higher % ADC than non-responding lesions 23.6% vs. À21%, respectively (P = 0.001). Conclusion: ADC is a reliable quantitative assay in assessing the efficacy of TACE and RFA in treating HCC and can replace contrast studies.
Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignant hepatic tumor which is in need for surgical resection and transplantation as the only potentially curative options; however, they are contraindicated in the majority of patients (1) . Only 10-20% of patients with hepatocellular carcinoma (HCC) or metastatic disease are eligible for hepatic transplantation (2) .
Imaging guided interventional procedures for treatment of HCC are radiofrequency ablation (RFA), ethanol injection, trans-arterial chemoembolization (TACE) and radioembolization which are not curative, but they increase survival and to down stage patients in order to be suitable for liver transplantation (3) .
Viable neoplastic tissue remains in some cases after TACE and RFA. Therapeutic efficacy after treatment is assessed by different imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI) and functional MRI including diffusion weighted image and apparent diffusion coefficient (DWI and ADC). Contrast enhanced CT and MRI are necessary with some limitations in evaluating the therapeutic efficacy (4) .
The mean ADC before and after TACE or RFA is significantly increased among patients with HCC (4) . ADC values map the thermally induced changes on water molecular motion in tissues are able to provide insight into tumor microstructure (5) .
The aim of this study was to assess the role of DWI and ADC value in evaluating HCCs post TACE and REA.
Patients and methods
This research is a prospective study conducted with institutional review board (IRB) approval and informed consents were taken from all patients.
Thirty-six patients in number with (40) HCCs were included in the study, which was conducted in Radiodiagnosis Department, Zagazig University Hospitals, during the period from February 2015 to October 2015. The patients were 28 males and 8 females, and their ages ranged from 40 to 75 year.
The HCCs were diagnosed according to characteristic imaging findings (early enhancement on dynamic contrast enhanced CT or MRI at the arterial phase with rapid washout at the portal venous phase) and positive Laboratory results for viral hepatitis and elevated level of alpha fetoprotein (AFP).
The 40 HCCs (mean diameter, 2.6 cm; range, 1.5-7.7 cm) were treated by interventional management, (28 HCCs) with TACE and (12 HCCs) with RFA.
We excluded Patients with contraindication to MRI study (pacemaker or vascular clips).
Patients were subjected to the following:
1. Clinical and laboratory assessment including the following: liver function tests, serum albumin, bilirubin and AFP level.
Radiological assessment:
All patients underwent baseline and follow-up MR imaging performed with a 1.5-T MR unit (Philips Achieva, superconducting MR imager). Abdominal coil was used with respiratory triggering. The imaging protocol included the following:
A. Non-contrast MR imaging preliminary to the diffusion weighted examination.
-T1-weighted images were performed with the following parameters: (TR = 400 ms, TE = 20 ms, 385 Â 385 mm field of view (FOV), 256 Â 256 matrix, section thickness 5-7 mm). -T2-weighted images with the following parameters (TR = 3000 ms, TE = 90, 385 Â 385 mm FOV, 256 Â 256 matrix and section thickness: 5-7 mm).
-STIR (short time inversion recovery) was performed using the following parameters: (TR = 418 ms, TE = 80, TI = 140 ms, 385 Â 385 FOV, 256 Â 256 matrix and section thickness 5-7 mm).
B. Diffusion weighted MR imaging (DWI) and ADC value calculation:
DWI was obtained using a transverse a single-shot echoplanar imaging with two b-values (500, 1000 mm 2 /s) applied in the z direction. These b-values were chosen to acquire images with a sufficient contrast-to-noise ratio. ADC maps were generated from the DWI, and values were recorded by placing ROIs over the center and peripheral area of the treated mass (Mean ADC of the ROIs was calculated), as observed on the axial image.
Evaluation with DWI was performed before TACE or RFA. The first follow-up was performed between four and six weeks post-interventional management by DWI and triphasic CT study. Further follow-up was done after 2 months using triphasic CT and/or DWI and ADC Value for the responding lesions, and we considered unchanged ADC value or the absence of tumor enhancement as a gold standard to confirm the absence of tumor activity or recurrence.
For evaluation of treatment response, in the follow-up study, responsive lesions were defined as complete and partial response tumors (>50% decrease in the product of the longest diameter and length of the perpendicular diameter of the lesion, or >50% increased necrosis), while non-responsive lesions were defined as stable and progressive disease.
The presence of any residual tumor and the extent of tumor necrosis were assessed. The apparent diffusion coefficient (ADC) values of the entire area of the treated mass and the viable and necrotic tumor tissues were recorded.
Changes in the ADC values, obtained 4-6 weeks after TACE or RFA, were determined by calculating the percent change in ADC from baseline study (before TACE or RFA), with each patient serving as his/her own control. The percent change in ADC (% ADC) from before to after TACE or RFA was calculated based on the following formula:
where ADC-b is ADC of HCC before TACE or RFA and ADC-a is ADC of HCC after TACE or RFA.
Statistical analysis
Data were checked, entered and analyzed using, Response Evaluation Criteria in Solid Tumors (RECIST) (6) . Data were expressed as mean ± SD for quantitative variables, numbers and percentage for qualitative ones. Unpaired t-test, paired t-test, Chi-squared (X 20 ) or fishers exact were used when appropriate. P < 0.05 was considered statistically significant.
Results
This study included 36 patients with 40 HCCs. They were 28 males (77.8%) and 8 females (22.2%), and their ranged between 40 and 75 years with a mean age 57.1 ± 10.9 years. The most common age group was 50-60 years (20 patients). The most common clinical symptoms were right hypochondrial pain, nausea, vomiting and fatigue. Laboratory findings included elevated alpha fetoprotein in 34 patients, elevated serum bilirubin in 8 patients, elevated liver enzymes in 30 patients and decreased total proteins in 11 patients, and 70% were treated by TACE as shown in Table 1 .
Diffusion-weighted imaging (DWI) was performed for all patients before TACE or RFA. The follow-up study was performed between four and six weeks post-interventional management ( Figs. 1 and 2 ).
The mean (±standard deviation) ADC in 40 HCCs before TACE or RFA was 1.27 ± 0.25 Â 10 À3 mm 2 /s using b value 500 and was 1.26 ± 0.28 Â 10 À3 mm 2 /s using b value 1000, with no significant difference from that in normal liver parenchyma (1.23 ± 0.26 Â 10 À3 mm 2 /s; P = 0.1).
On the follow-up study (4-6 weeks post-interventional management) of the 40 HCCs evaluated by DWI and ADC value calculation, 32 HCCs responded to treatment and 8 HCCs had not.
With b value 500, the mean ADC value before treatment did not differ significantly between responding (1.27 ± 0.26 Â 10 À3 mm 2 /s) and non-responding lesions (1.27 ± 0.20 Â 10 À3 mm 2 /s; P = 0.97). While with b value 1000, there was a significant difference with higher mean ADC values before interventional management in responding lesions than in non-responding (1.32 ± 0.28 Â 10 À3 mm 2 /s in responding lesions and 1.04 ± 0.00 Â 10 À3 mm 2 /s in non-responding, respectively; P = 0.03).
Responding lesions showed significantly larger percent change in ADC (% ADC) than in non-responding lesions, and it was 18.9% vs. 5.7%, respectively (P = 0.01) using b value 500 and was 23.6% vs. (À21%), respectively (P = 0.001) using b value 1000.
Most of the lesions (90%) were of low signal intensity on T1WI before treatment. After treatment, 60% of them retained low signal intensity, while the remaining became of high or intermediate signal on T1WI. The high signal intensity represents subacute hemorrhage.
There was significant difference of T1WI signal intensity before and after treatment (p < 0.05) as shown in Table 2 .
Most of the lesions (80%) were of high signal intensity on T2WI before treatment. After treatment, 60% of them retained high signal intensity, while the remaining became of low or intermediate signal which is not conclusive and may represent Liquefactive necrosis or residual tumor. There was significant difference of T2WI signal intensity before and after treatment (p < 0.05) as shown in Table 3 .
All lesions (100%) were of high signal intensity on DWI before treatment, 90% of them were still high after treatment, while the remaining became of low signal intensity. This is not conclusive and should be enforced by quantitative diffusion using ADC value measurement (Table 4 ).
Mean ADC value before treatment was 1.27 ± 0.25 Â 10 À3 mm 2 /s (mean ± SD), while after treatment it was 1.46 ± 0.3 Â 10 À3 mm 2 /s (mean ± SD). The % ADC change was 19.8% (±7.05) which is significant by statistical analysis ( Table 5 ).
Mean ADC value before treatment was 1.26 ± 0.28 Â 10 À3 mm 2 /s (mean ± SD), while after treatment it was 1.46 ± 0.24 Â 10 À3 mm 2 /s (mean ± SD). The % ADC change was 19.7% (±6.01) which is significant by statistical analysis ( Table 6 ).
The mean ADC value of the lesions treated with TACE was 1.2 ± 0.22 Â 10 À3 before treatment and 1.47 ± 0.33 Â 10 À3 after treatment with significant difference (P = 0.02), while in lesions treated with RFA it was 1.375 ± 0.26 Â 10 À3 before treatment and 1.44 ± 0.01 Â 10 À3 after treatment with significant difference (P = 0.04) as shown in Table 7 .
The mean ADC value of the lesions treated with TACE was 1.225 ± 0.24 Â 10 À3 mm 2 /s (mean ± SD) before treatment and 1.435 ± 0.26 Â 10 À3 mm 2 /s (mean ± SD) after treatment with significant difference (P = 0.004).
While in lesions treated with RFA it was 1.33 ± 0.24 Â 10 À3 mm 2 /s (mean ± SD) before treatment and 1.52 ± 0.1 Â 10 À3 mm 2 /s (mean ± SD) after treatment with significant difference (P = 0.03) as shown in Table 8 .
The mean ADC value (at b value 500) of the responding HCCs with no residual tumor was 1.32 ± 0.28 Â 10 À3 mm 2 /s (mean ± SD) before treatment and 1.54 ± 0.12 Â 10 À3 mm 2 /s (mean ± SD) after treatment with statistically significant difference (P = 0.02).
While in non-responding HCCs with residual tumor it was 1.04 ± 0.0 Â 10 À3 mm 2 /s (mean ± SD) before treatment and 1.1 ± 0.07 Â 10 À3 mm 2 /s (mean ± SD) after treatment with non-significant difference (P = 0.06) as shown in Table 9 .
The mean ADC (at b value 1000) of the responding HCCs (N = 32) with no residual tumor was 1.27 ± 0.26 Â 10 À3 mm 2 /s (mean ± SD) before treatment and 1.57 ± 0.22 Â 10 À3 mm 2 /s (mean ± SD) after treatment with statistically significant difference (P = 0.002).
While in non-responding HCCs (n = 8) with residual tumor, it was 1.27 ± 0.2 Â 10 À3 mm 2 /s (mean ± SD) before treatment and 1.002 ± 0.005 Â 10 À3 mm 2 /s (mean ± SD) after treatment with non-significant difference (P = 0.18) as shown in Table 10 .
Discussion
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors all over the world (7) .
Most of patients with hepatocellular carcinoma are unfit for surgery or liver transplant, and the alternative treatment is locoregional therapy (2) . Post loco-regional therapy or systemic therapy evaluation is mandatory to evaluate its success and whether further treatment is needed (2) . RF ablation (RFA) is the most widely used ablation therapy, and consists of placing a needle electrode directly into the tumor, guided by US or CT, and heating tissue to temperatures exceeding 60°C to induce coagulative necrosis of the tumor. Ablation zone should be 5-10 mm larger in comparison with the pre-existing tumor (8) .
Trans-arterial chemoembolization (TACE) consists of trans-arterial administration of a mixture of chemotherapy (Doxorubicin or Cisplatin in most cases) and iodized oil (Lipiodol, Guerbet, France), followed by embolizing agents 9) . MRI is one of the most valuable techniques in the evaluation of post therapeutic response (5) . DWMRI is the most accurate non-invasive method to evaluate tumoral cellularity, particularly in patients with renal impairment and cannot receive CT contrast material (10) .
The current study included 36 patients (28 males and 8 females) with 40 HCC lesions, and 28 lesions were treated with TACE and 12 lesions with RFA.
Their ages ranged from 40 to 75 years and the mean age was 57.1 years, which means that hepatic tumors are more predominant after the age of 50 which was in line with Miller et al. (11) who performed a study including 382 patients with age ranging from 15 to 88 years and mean age was 59.2 years. In addition, Vergara et al. (12) carried out a study including 26 patients with age ranging from 30 to 73 years and the mean age was 51.5 years. Koike et al. (13) also carried out a study including 70 patients with age ranging from 39 to 86 years and mean age 65.3 years.
DWI and ADC value measurements were used 4-6 weeks after TACE or RFA. Kamel et al. (14) found that ADC significantly increased within the first day after TACE and reaches its maximum after 2 weeks, and this was followed by gradual decreases to reach the pre-therapeutic level. Lu et al. (15) stated that there were significant differences from the pretreatment ADC values and 1 and 6 months after RF ablation of the HCC.
Post TACE or RFA for HCC treatment there were different patterns of T1 and T2 signal intensity. Hypointense T2 weighted images suggest coagulative necrosis while hyperintense T2 weighted images represent residual tumor tissue and may also represent hemorrhage, tumor liquefactive necrosis or inflammatory process Vossen et al. (5) . In our study, the signal intensity on T1 and T2 weighted images was significantly variable. Thirty-six HCCs lesions (90%) showed low signal intensity on T1WI before treatment and 24 HCCs (67%) of them retained low signal intensity after treatment while 8HCCs (20%) depicted high signal intensity which represents subacute hemorrhage, and the reminder 4 lesions (10%) depicted intermediate signal intensity.
On T2WI, 32 HCCs (80%) lesion showed high signal intensity before treatment which represents active tumoral tissue and varied after treatment with 24 out of 32 HCCs (75%) retained high signal intensity which is not conclusive and may correspond to residual tumor. However, this hyperintensity can also represent hemorrhage, Liquefactive necrosis or inflammatory infiltration. While 12 HCCs (30%) showed low signal after treatment, with statistically significant difference (p < 0.05), 8 HCCs (20%) were intermediate before treatment, 50% of them retained intermediate signal, and so we cannot depend on the signal intensity only in monitoring the effect of treatment.
In this study we use high b values (500 and 1000 s/mm 2 ) to overcome the effect of capillary perfusion and water diffusion in extracellular extravascular space, as high b value will result in reduction in signal from moving protons in the bile ducts, cysts, vessels, and fluid in the bowel. This will result in an increased contrast between the lesion and liver. This was similar to the b value used in studies carried out by Koike et al. (13) , Demir et al. (16) , and Hosni (17) .
In our study we found that the mean ADC value of the liver parenchyma was (mean ± SD) 1.23 ± 0.26 Â 10 À3 mm 2 /s which was in line with the study done by Lu et al. (15) who reported that the mean ADC value of normal liver was (mean ± SD) 1.286 ± 0.234 Â 10 À3 mm 2 /s. The mean (±standard deviation) ADC in 22 HCCs before TACE or RFA was 1.27 ± 0.25 Â 10 À3 mm 2 /s using b value 500 and was 1.26 ± 0.28 Â 10 À3 mm 2 /s using b value 1000, with no significant difference from that in normal liver parenchyma (1.23 ± 0.26 Â 10 À3 mm 2 /s; P = 0.1). This was similar to Kubota et al's (4) study, who found that the mean (±standard deviation) ADC in 36 HCCs from 25 patients before TACE was 1.27 ± 0.395 Â 10 À3 mm 2 /s, with no significant difference from that in normal liver parenchyma (1.286 ± 0.234 Â 10 À3 mm 2 /s; P = 0.901).
The mean ADC value before management did not differ significantly with b value 500 between responding (1.27 ± 0.26 Â 10 À3 mm 2 /s) and non-responding lesions (1.27 ± 0.20 Â 10 À3 mm 2 /s, P = 0.97). While with b value 1000, there was a significant difference with higher mean ADC values before interventional management in responding lesions than in non-responding (1.32 ± 0.28 Â 10 À3 mm 2 /s in responding lesions and 1.04 ± 0.00 Â 10 À3 mm 2 /s in non-responding, respectively; P = 0.03). This was in agreement with the results of Kubota et al. (4) , who found that the ADC showed no significant difference between responding (1.222 ± 0.355 Â 10 À3 mm 2 /s) and non-responding lesions (1.357 ± 0.46 Â 10 À3 mm 2 /s; p = 0.33) using b value 500.
On the short term follow-up study of the 40 HCC lesions, 32 HCCs responded to treatment and 8 HCCs had not according to DWI and ADC value calculation.
In our study, responding lesions showed significantly higher percent change in ADC (% ADC) than in non-responding lesions. It was 18.9% vs. 5.7%; P = 0.01 using b value 500 and 23.6% vs. (À21%), respectively using b value 1000; P = 0.001. Kubota et al. (4) found that the mean (±standard deviation) ADC in 36 HCCs from 25 patients before TACE was 1.27 ± 0.395 Â 10 À3 mm 2 /s, while after TACE responding lesions showed significantly higher % ADC than in non- 
